Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Castration-resistant Prostate Cancer × radium Ra 223 dichloride × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 39 Prostatic Neoplasms, Castration-Resistant 5 Neoplasm Metastasis 5 Breast Neoplasms 4 Metastatic Castration-resistant Prostate Cancer 3 Prostate Carcinoma Metastatic to the Bone 2 Neoplasms 2 Multiple Myeloma 2 Metastatic Castration-resistant Prostate Cancer (mCRPC) 2 Hormone Refractory Prostate Cancer 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Bone Metastatic Castration-resistant Prostate Cancer 2 Thyroid Neoplasms 1 Prostate Cancer Metastatic to Bone 1 Prostate Adenocarcinoma 1 Pain 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Fractures, Bone 1 Fatigue 1 Castration-resistant Prostate Cancer 1 Castrate-Resistant Prostate Cancer 1 Bony Metastases From Castrate Refractory Prostate Cancer 1 Bone Neoplasms 1 Bone Diseases 1 Anatomic Stage IV Breast Cancer AJCC v8 1 Advanced Prostate Cancer 1

Interventions

enzalutamide 4 Radiotherapy 2 Metastasectomy 2 radium Ra 223 dichloride 1 pembrolizumab 1 disitamab vedotin 1 dactolisib 1 abiraterone 1 VT-464 1 Radium-223 1 Radiosurgery 1 NVP-BKM120 1 Ketoconazole 1 Hydrocortisone 1 Flutamide 1 Cyclophosphamide 1 Crizotinib 1 Control Groups 1 Carboplatin 1 Calcitriol 1 Blood Specimen Collection 1 Albumin-Bound Paclitaxel 1 Abiraterone Acetate 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04232761 2024-07-17

RAPIT

Bayer

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡